

JAN 30 1990

THE

# CANCER LETTER

P.O. BOX 15189 WASHINGTON, D.C. 20003 TELEPHONE 202-543-7665

Vol. 16 No. 4  
Jan. 26, 1990

(c)Copyright 1990 Cancer Letter Inc.  
Price \$195 Per Year US, Canada.  
\$220 Per Year Elsewhere

## First CCOP 3 Returns In; Payline Not Yet Determined; Goes To NCAB On Jan. 30

The first returns are in on "CCOP 3," the massive recompetition of the Community Clinical Oncology Program. At press time, **The Cancer Letter** had obtained the priority scores of 23 applicants, 22 of which are  
(Continued to page 2)

### In Brief

## McIntyre To Replace Frei As Group Chairman; Abeloff, Murphy Nominated For ASCO Presidency

EMIL (TOM) FREI will give up the chairmanship of Cancer & Leukemia Group B when his current term expires this year. He will be replaced by Ross McIntyre, director of the Norris Cotton Cancer Center at Dartmouth. Frei, director and physician in chief of Dana-Farber Cancer Institute at Harvard, said he will continue as an active member of the group, "although not as active as one is as chairman." He is completing his second consecutive five year term, and is prevented by the group's constitution from serving a third term. . . . **ASCO CANDIDATES** for 1990 elections have been selected by the nominating committee. Nominees for president are Martin Abeloff, Johns Hopkins Oncology Center, and Sharon Murphy, Children's Memorial Hospital, Chicago. Nominees for Board of Directors are Fred Applebaum, Fred Hutchinson Cancer Research Center; Charles Cobau, Toledo, OH; Sarah Donaldson, Stanford Univ.; Nancy Kemeny, Memorial Sloan-Kettering; Glenn Steele, New England Deaconess Hospital; and Daniel Von Hoff, Univ. of Texas Health Science Center. . . . **LOUIS SULLIVAN**, HHS secretary, took on a tobacco company last week and won. Sullivan assailed R.J. Reynolds Tobacco Co. for "deliberately and cynically" test-marketing a new cigarette brand, Uptown, primarily aimed at blacks, and for "promoting a culture of cancer" using "slick and sinister advertising." The day after Sullivan's statement, the company cancelled planned test marketing of the brand in Philadelphia. "Uptown's message is more disease, more suffering, and more death for a group already bearing more than its share of smoking related illness and mortality," Sullivan said. Reynolds officials complained that the brand received "unfair and biased attention." . . . **NATIONAL CANCER Advisory Board meeting** will be held Jan. 29-30 in Bldg. 31 Rm 10. Open times are 8:30 a.m.-4:30 p.m. on Jan. 29 and 1-4:30 p.m. Jan. 30. Location and times of committee meetings: Committee on Cancer Centers, Jan. 28, 7 p.m. in Bldg. 31 Rm 7. Working Group of the Committee on Agenda, Jan. 29, noon-1 p.m., Bldg. 31 Rm 10A03. Committee on Planning & Budget, Jan. 29 following NCAB meeting, Bldg. 31 Rm 7. AIDS Committee, Jan. 29, 6 p.m., Bldg. 31 Rm 8.

Organ Systems Program Adds Workshops On Lung, Colorectal Cancer . . . Page 2

'Dear Dr. Bick': Letters Reflect Turmoil Over Conflict Of Interest . . . Page 3

Cancer Meetings For Feb., March, Future . . . Page 5

RFPs Available . . . Page 7

## First CCOP 3 Returns In; Ochsner Leads Pack With Score Of 116

(Continued from page 1)  
in the probable funding range.

Leading the pack this time, with an exceptionally good score of 116, was the Ochsner CCOP of New Orleans, with Carl Kardinal the principal investigator. A perfect score would be 100. The closest to Ochsner's reported so far is 126, and they range up to 278.

The National Cancer Advisory Board is scheduled to act on the CCOP awards next Tuesday (Jan. 30). Until then, the payline probably will not be made available. NCI staff this week were still pouring over the applications, trying to spread the budget over as many CCOPs as possible.

Where a CCOP finishes in the scoring is particularly important this time. The top one third will receive five year awards; the middle third four years; and the rest three years. NCI would like to move them all, eventually, into five years, with 20 percent a year up for renewal. It probably will work out that three year awards still will be made to those deemed risky although in the funding range.

The payline in CCOP 2 was 232, but eight of the original 52 awards were exceptions--those with scores above the payline but funded to meet geographic or demographic goals or possibly to correct what may have been determined inequities in the review. Three more were funded about a year later.

Following are the CCOPs, in addition to Ochsner,\* with scores well under 232, which probably means they will be funded (the highest is 220). It is *The Cancer Letter's* policy not to publish scores of individual awardees, except in the case of the highest score. This is a partial list only; those with apparently fundable scores will be published as they become available. Those who should be on this list but are not

are invited to call *The Cancer Letter* at 202/543-7665.

These are in no particular order, by priority score or any other reason:

Greater Phoenix CCOP, David King, PI;  
Kansas City CCOP, Robert Belt, PI;  
Natalie Warren Bryant CCOP, Tulsa, Alan Keller, PI;

Northwest CCOP, Tacoma, WA, Erving Pierce, PI;  
Sacramento CCOP, Vincent Caggiano, PI;  
Spartanburg, SC, CCOP, John McCulloch, PI;  
Virginia Mason CCOP, Seattle, Albert Einstein, PI;  
Wichita CCOP, Henry Hynes, PI;

Allegheny CCOP, Pittsburgh, Reginald Pugh, PI;  
Atlanta Regional CCOP, Ernest Franklin, PI;  
Central Illinois CCOP, Gale Katterhagen, PI;  
Central Los Angeles CCOP, Cary Presant, PI;  
Columbia River CCOP, Portland, OR, Gordon Doty, PI;

Dayton CCOP, James Ungerleider, PI;  
Eastern Maine Medical Center CCOP, Philip Brooks, PI;

Grand Rapids CCOP, James Borst, PI;  
Twin Tiers CCOP, Binghamton, NY, and Sayre, PA, Bruce Boselli, PI;

Bergen-Passaic CCOP, Hackensack, NJ, Richard Rosenbluth, PI;

Indianapolis CCOP, Lloyd Everson, PI;  
San Francisco CCOP, Peter Eisenberg, PI.  
Columbus, OH, CCOP, Jerry Guy, PI.  
Mt. Sinai CCOP, Miami, Mark Wallack, PI.

Individual CCOP budgets approved in the peer review were "appreciably higher" than those in the previous round. NCI's most difficult task is to determine whether and how much to cut from the recommended levels. If the recommended levels are allowed to stand, substantially fewer awards will be made.

## Organ Systems Program Adds Two Workshops--Lung, Colorectal Cancer

Two workshops have been added to the Organ Systems Program's schedule for this year, for lung and colorectal cancer. The lung workshop probably will be held in the fall, colorectal in the spring.

The program had previously scheduled a workshop on prostate cancer for May and another on breast cancer for September.

The lung workshop is the first time that that site will be brought into the Organ Systems Program. Although it is the No. 1 cancer killer in the U.S., NCI and its advisors rejected establishing a working group for it because (a) they felt there already was enough

### THE CANCER LETTER

Editor: Jerry D. Boyd

Associate Editors:

Kirsten B. Goldberg, Patricia Williams

Editorial/Subscriptions Office

PO Box 15189, Washington, DC 20003

Tel: (202) 543-7665 Fax: (202) 543-6879

ISSN 096-3917. Published 48 times a year by The Cancer Letter Inc., also publisher of *The Clinical Cancer Letter* and *AIDS Update*. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form (electronic, mechanical, photocopying, facsimile, or otherwise) without prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.

research under way and the field did not need stimulation; (b) the research opportunities were not there; or (c) since the cause of most lung cancer had been established and thus prevention was clear cut, limited research dollars should be spent elsewhere.

Those views have changed although the facts have not, and the workshop will look for gaps and research opportunities and attempt to prioritize them, the mission of all the program's workshops.

Colorectal cancer was included in the old Organ Systems Program, with the Large Bowel Cancer Working Group. That group, like all the others in the former version of the program, has been disbanded. Some of the members of that group will be invited to participate in the workshop, along with other scientists outside NCI, and NCI staff members.

Ad hoc working groups will be named from the participants in each workshop, with the job of synthesizing the discussions, and drafting recommendations for new research efforts.

Those recommendations will eventually turn up as concept proposals submitted to the appropriate NCI division board of scientific counselors. Those could be in the form of RFAs (grants), RFPs (contracts), or PAs (program announcements).

NCI decided last year that concept proposals going then to the BSCs would be program announcements. RFAs require set aside funds, and the NCI budget was determined insufficient to assure that a reasonable number of grants from RFAs could be funded. Program announcements generate grant applications which compete in the regular RO1 or PO1 pool.

Andrew Chiarodo, chief of the Organ Systems Branch in the Div. of Cancer Biology & Diagnosis where the program is now housed, said that the decision does not necessarily apply this year, and that RFAs may come out of the 1990 workshops.

## **'Dear Dr. Bick': Letters To NIH Debate Need For Conflict Guidelines**

A nine-inch stack of more than 750 letters from universities, research institutions, scientific and medical associations, individual scientists, biotechnology firms, pharmaceutical and chemical companies, venture capitalists, lawyers, Michael Dukakis, the South Montgomery County (TX) Chamber of Commerce and one cancer patient convinced HHS officials not to implement the conflict of interest guidelines proposed last September.

The letters started coming in soon after the guidelines were published in the Sept. 15 issue of the

"NIH Guide to Grants & Contracts." The letters, following instructions in the "NIH Guide," were addressed to Katherine Bick, NIH deputy director for extramural research.

The proposed guidelines prohibited grantees from having personal equity in a company "that would be affected by the outcome of the research or that produces a product or equipment being evaluated in the research project." The prohibition would apply to any "investigator, key employee, consultant, or other persons with primary research, management, advisory, supervisory, or purchase authorization responsibilities, or their spouses, dependent children, or other dependents."

All but a handful of letters supported the guidelines as written. Some letters tried humor to sway opinion. "Quickly I must dash off this letter concerning the conflict of interest guidelines policies, before I dash madly to my stockbroker and order him to sell off my portfolio," wrote John Ellerton, principal investigator of the Southern Nevada Cancer Research Foundation Community Clinical Oncology Program. After making his case against the guidelines, Ellerton concluded: "I urge you strongly to cease and desist in the development of such nonsense."

Others invoked the threat of foreign competition. The American Assoc. of Cancer Institutes wrote that the guidelines "will severely undercut good research and the net effect will be a major transfer of biomedical research leadership from the U.S. to other countries not faced with such crippling limitations on innovation."

In his letter to Bick, Massachusetts Governor Michael Dukakis wrote that, "There is considerable agreement within Massachusetts's research community that the regulations proposed will cut off most or all relationships between emerging technology companies and academic researchers. Massachusetts--and the nation--is relying increasingly on such relationships to produce world class products that will allow us to compete internationally in the future."

At least half a dozen letterwriters, including Roy Wu, program director in NCI's Cancer Therapy Evaluation Program, and Harris Busch, president of the American Assoc. for Cancer Research, accused NIH of "throwing the baby out with the bath water."

Robert Schimke of Stanford Univ. and a member of the Div. of Cancer Treatment Board of Scientific Counselors, scolded Bick for the proposal's ambiguous wording. "I would hope that when the actual guidelines are published, they can be made clear and crisp, so that persons and institutions reading them can clearly understand them. I say this because 'federaleze'

can be obscure and confusing," he wrote.

The President's Cancer Panel threw its weight into the debate, expressing its "most serious reservations" about the guidelines and saying the proposed regulations "are moving into areas of regulatory conduct best left to the sponsoring institutions."

Responding to the criticism, HHS Secretary Louis Sullivan asked NIH to rewrite the proposed guidelines for grantees in a way that will "properly treat potential abuse while keeping the research process free of unnecessary burdens and disincentives" (*The Cancer Letter*, Jan. 12).

Sullivan said he believes "any change in this important area should undergo the fullest consideration and comment."

Judging from the variety of comments NIH received from those involved in cancer research, whose letters made up a substantial proportion of those submitted, even substantially rewritten guidelines will not please everyone.

Div. of Cancer Treatment Director Bruce Chabner, echoing many of the letterwriters, wrote, "The proposed guidelines would create conflicts that could only be resolved by separation of academia and industry, and this in turn would have a devastating negative effect on biotechnology in this country."

Chabner noted that two prominent NCI grantees, Ivor Royston of Univ. of California (San Diego) and Ron Levy of Stanford Univ., have financial interests in IDEC Pharmaceuticals Corp. "Would they be forced to make a choice between academia and industry?" he asked.

However, the DCT Board, in a letter written by its chairman, John Niederhuber, said it favored "prohibiting entrepreneurial activities by investigators that involve the potential for personal financial gain from research supported by public funds." The board said it believed investigators should be allowed to receive research support from from other sources, "in a way that excludes stock options, management positions, or arrangements leading to a share in ownership of companies, which would place the investigator in a situation to benefit financially from the commercial success of his/her research efforts supported by PHS funds."

Royston, director of the Clinical Immunology Program at UCSD and co-founder of Hybritech Inc. and IDEC, wrote in to defend the practice of equity holdings. "In the case of IDEC Pharmaceuticals Corp., I have had NIH grants to study customized anti-idiotype antibody therapy of lymphoma in man. NIH, however, could not support the \$25,000 cost per patient to produce such antibodies. Therefore, I

interested venture capitalists in forming a company that would commercially develop such antibodies.

"Again, only if I received equity in the proposed company as a commitment to IDEC could such a company be initiated. Moreover, existing pharmaceutical and biotechnology companies, including Hybritech, were not interested in customized monoclonal antibodies. As a consequence, the antibodies have been manufactured by IDEC and the NIH has supported the clinical trials," Royston wrote. "This scenario has been a very good example of a university-government-industrial relationship. As a result, many patients have benefited from this new lymphoma therapy that could only result from such a relationship."

Noting that his research is done with many collaborators, Royston said, "I could not bias our research even if I wanted to."

A statement submitted by Biogen Inc., which produces alpha, beta and gamma interferon and other products, said that if the proposed regulations had been in effect 10 years ago, "Biogen would never have been organized."

William Otterson of La Jolla, CA, the only cancer patient to enter the debate, wrote that he has been under the care of Sydney Salmon, director of the Univ. of Arizona Cancer Center, for multiple myeloma. "To preserve my hair, I used the cold cap designed by Dr. Salmon and a San Diego company." Currently, Otterson is on alpha interferon. "As you know, plentiful supplies of alpha interferon are an outgrowth of the Boyer/Cohn work on recombinant DNA, probably funded by you. Some day, I may benefit from an anti-id produced by IDEC. I'm glad you're funding anti-id research.... But in your quest to protect me from the 'charlatans of research,' please don't discourage NIH funded researchers from working with and benefitting from the private sector."

One of the guidelines' defenders among the cancer research community was Charles Moertel of the Mayo Clinic. "I cheer you on in this endeavor," he wrote to Bick. However, he was concerned that the guidelines still left "very large loopholes" for investigators to accrue wealth from firms that have a direct interest in research results. "These include such things as luxurious trips for investigators and their family members" to meetings, paid for by companies.

"I also feel you should address the very common practice of laundering large amounts of money to be given by commercial institutions through universities or other nonprofit groups who then in turn present it to the investigator in the form of large honoraria." Moertel also suggested that the prohibition on equity

holdings apply to the investigator's parents. "The investigator can enrich himself just as easily through equities held by his parents which will later come to the investigator in the form of an estate or tax free gifts."

Other writers were concerned about the effect of the guidelines on the National Cooperative Drug Discovery Groups. T.W. Doyle, director of antitumor chemistry at Bristol-Myers Squibb Co., noted that his firm is involved with two NCDDG grants.

Instead of prohibitions on equity holdings, simple disclosure and signing of conflict of interest statements should suffice, many letterwriters said. "The focus for all concerned should be disclosure, not proscription of important private sector initiatives," the President's Cancer Panel wrote.

However, not everyone favored financial disclosure as proposed in the guidelines. Susan Charrier, an administrator of the Fred Hutchinson Cancer Research Center, determined the amount of space that would be required to store the paperwork for the guidelines' proposed "full disclosure of all funding other than that from the applicant institution" required of awardees, their spouses and dependent children.

Fred Hutchinson negotiated 358 grant and contract applications in 1989, Charrier wrote. Assuming each application involved one principal investigator and two cooperating investigators, two key employees and one consultant, and assuming each had one spouse and two dependents, the total number of disclosures per grant or contract would be 18. That means a total of 6,444 disclosures per year. Assuming 500 disclosures would take up 4 inches of file cabinet space, "If each disclosure was one page, the room required to store this information would require about 4 1/2 feet of file space per year," Charrier concluded.

Frederick Becker, vice president for research at Univ. of Texas M.D. Anderson Cancer Center, said the disclosure requirement "presents an overwhelming recordkeeping task."

One letter took a historical, rather than a logistical, approach. Ross McIntyre, director of the Norris Cotton Cancer Center, urged Bick to "view the subject from a vantage point far enough removed from the convenient legal jargon....First, some perspective. I'll skip the Greeks and go right to Chaucer's description of the doctor in about 1400 A.D.:

"Ful reddy hadde he his apothecaries  
To sende him drogges and his letuaries,  
For ech of hem made other for to winne;  
His friendschipe nas nat newe to beginne.  
(He had his apothecaries quite ready  
to send him drugs and medicines,

for each of them helped the other to profit;  
their friendship was not recently begun.)"

The Senate Committee on Labor & Human Resources, chaired by Sen. Edward Kennedy (D-MA) wrote to Sullivan after the guidelines were withdrawn suggesting that "a panel of experts be convened to address the issues."

## NCI Advisory Group, Other Cancer Meetings For Feb., March, Future

**FDA Oncologic Drugs Advisory Committee**--Feb. 1-2, Parklawn Bldg. Rms D & E, Rockville, MD. Open 8:30 a.m. Feb. 1, 8 a.m. Feb. 2.

**Breast Cancer: Cellular and Molecular Biology**--Feb. 3-8, Tamaron, CO. Contact UCLA Symposia, 2032 Armacost Ave., Los Angeles, CA 90025, phone 213/207-2397.

**Society of Gynecologic Oncologists Annual Meeting**--Feb. 4-7, Fairmont Hotel, San Francisco, CA. Contact SGO, 111 E. Wacker Drive, Suite 600, Chicago, IL 60601.

**Assoc. for Research in Otolaryngology 1990**--Feb. 4-8, St. Petersburg, FL. Tradewinds Hotel. Contact Dr. Richard Fabian, Mass. Eye & Ear Infirmary, 243 Charles St., Boston, MA 02114, phone 617/573-3972.

**Oncology Nursing Conference**--Feb. 6-9, Houston, TX. Wyndham Greenspoint Hotel. Contact Jeff Rasco, Conference Services, Box 131, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, phone 713/792-2222.

**Clinical Laboratory Molecular Analysis**--Feb. 7-9, San Diego, CA. San Diego Princess Hotel. Contact Bonny Mower, Dept. of Academic Affairs, Box 400S, Scripps Clinic & Research Foundation, 10666 North Torrey Pines Rd., La Jolla, CA 92037, phone 619/554-8556.

**Indian Society of Oncology/Workshops on Pain and Lasers**--Feb. 7-12, Ahmedabad, India. Contact Gujarat Cancer & Research Institute, Civil Hospital, Campus, Awarwa, Ahmedabad 380 016 India.

**Prostate Cancer: Controversies in Diagnosis & Treatment**--Feb. 9-10, Orlando, FL. Peabody Hotel. Contact Imedes USA Inc., 5815 Wills Orchard Rd., Cumming, GA 30130, phone 404/751-7332.

**Brain Tumor Conference: A Living Resource Guide**--Feb. 9-10, San Francisco, CA. San Francisco Hilton. Contact National Brain Tumor Foundation, 323 Geary St. Suite 510, San Francisco, CA 94102, phone 415/296-0404.

**Cancer Management Course**--Feb. 10-11, Honolulu, HI. Contact Dr. Scott Hundahl, American College of Surgeons, Cancer Dept., 55 E. Erie St., Chicago, IL 60611, phone 312/664-4050.

**Steroid Receptors, Transcription Factors and Gene Expression**--Feb. 10-13, Catamaran Resort Hotel, San Diego, CA. Contact American Assn. for Cancer Research, 330 Market St. 2nd Floor, Philadelphia, PA 19106, phone 215/440-9300.

**Div. of Cancer Treatment Board of Scientific Counselors**--Feb. 12-13, NIH Bldg 31C, Rm 6. Open 8:30 a.m.-3:30 p.m. Feb. 12 and 8 a.m.-noon Feb. 13.

**New Trends in the Management of Cancer**--Feb. 13-24, Cairo, Egypt. Contact Prof. Shawki El-Haddad, Kasr-El-Aini Center of Oncology and Nuclear Medicine, El-Manial, Cairo, Egypt.

**Cancer Care: Differentiating Your Program**--Feb. 14-16, San Diego, CA. Sheraton Grand Hotel on Harbor Island. Contact Ron Gilden or Joanna Mitchell, CDP Services, 1050 Crown Pointe Parkway, Suite 210, Atlanta, GA 30338, phone 404/391-9872.

**American Assoc. for the Advancement of Science**--Feb. 15-20,

New Orleans, LA. Contact Joan Wrather, AAAS, 1333 H St. NW, Washington, D.C. 20005, phone 202/326-6440.

**Southwest Oncology Nursing Symposium: Challenges and Opportunities in Cancer Nursing II**--Feb. 16-17, Phoenix, AZ. Contact Debbie Todd, Outreach Services, Good Samaritan Regional Medical Center, 1111 E. McDowell Rd., Phoenix, AZ 85006, phone 602/239-5994.

**Meeting Patient and Family Support and Referral Needs**--Feb. 16 and 23, Univ. of Pittsburgh School of Nursing, Victoria Bldg, Pittsburgh, PA. Contact Denise Brooks, 412/624-7899.

**Clinical Hematology and Oncology**--Feb. 19-21, La Jolla, CA. Sheraton Grande. Contact Bonny Mower, Dept. of Academic Affairs, Scripps Clinic, 10666 North Torrey Pines Rd., La Jolla, CA 92037, phone 619/544-8556.

**Novel Chemotherapeutic Approaches in Treatment of Colorectal Cancer**--Feb. 23-24, Doral Ocean Beach Resort, Miami Beach, FL. Doral Ocean Beach Resort. Contact Div. of Continuing Medical Education (D23-3), Univ. of Miami School of Medicine, PO Box 016960, Miami, FL 33101, phone 305/547-6706.

**24th Annual Clinical Symposium**--Feb. 23, St. Jude Children's Research Hospital, Memphis, TN. Contact Director, St. Jude Children's Research Hospital, Box 318, Memphis, TN 38101, phone 901/522-0300.

**UICC Cancer Nursing Workshop**--Feb. 25-30, Mexico City, Mexico. Contact Dr. J. de la Garza, Instituto Nacional de Cancerologia, Av. San Fernando No. 2, Tlalpan, 14000 Mexico D.F., Mexico.

**Temporal Control of Drug Delivery**--Feb. 26-28, New York City, Sheraton Centre Hotel. Contact Conference Director, New York Academy of Sciences, 2 East 63rd St., New York, NY 10021, phone 212/838-0230.

**Supportive Care in Cancer Patients**--Feb. 28-March 3, St. Gallen, Switzerland. Contact Congress Secretariat "SUP-90," Med. Klinik C, Kantonsspital, 9007 St. Gallen, Switzerland.

**Current Approaches to Radiation Oncology, Biology & Physics**--Feb. 28-March 2, San Francisco, CA. Nikko Hotel. Contact Crest International, 940 Emmet Ave. Suite 14, Belmont, CA 94002, phone 800/222-8882 outside CA or 415/595-2704 inside CA.

**Div. of Cancer Etiology Board of Scientific Counselors**--March 1-2, NIH Bldg 31 Rm 10. Open 1 p.m.-recess March 1, 9 a.m. to adjournment March 2.

**ICN-UCI International Conference on Virology: Viruses That Affect the Immune System**--March 1-3, Newport Beach, CA. Hotel Meridien. Contact Nita Driscoll, ICN-UCI Symposium Office, Cancer Research Institute, Univ. of California, Irvine, CA 92717, phone 714/856-5886.

**Advances in Immunodiagnosis and Immunology of Cancer**--March 1-3, Fort Lauderdale, FL. Contact Janice Ford, Wistar Institute, 3440 Market Street Suite 420, Philadelphia, PA 19104, phone 215/662-6904.

**Columbus Cancer Conference: Diagnosis & Treatment of Gynecologic & Prostate Cancer**--March 2, Columbus, OH. Embassy Suites Hotel. Contact Riverside Methodist Hospitals, phone 614/261-4475

**Biology of Human Malignant Lymphomas**--March 5-6, Bordeaux, France. Contact F. Capuron, Unite 117 INSERM, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France.

**Combining Biological Response Modifiers With Cytotoxics in the Treatment of Cancer: Developing a Rational Approach to a New Therapy**--March 5-7, Baltimore, MD, Omni Inner Harbor Hotel. Contact Abbe Smith or Debra Casey, TRI, phone 301/770-3153, or Dr. Mace Rothenberg, phone 301/496-6404.

**7th Annual Advances in Cancer Treatment Research/2nd Autologous Bone Marrow Transplantation Symposium**--March 7-9, Grand Hyatt Hotel, New York City. Contact Office of Continuing

Medical Education, Albert Einstein College of Medicine, 3301 Bainbridge Ave., Bronx, NY 10467, phone 212/920-6674.

**Sixth International Conference on Adjuvant Therapy of Cancer**--March 7-10, Arizona Cancer Center, Tucson, AZ. Abstract deadline Dec. 1. Contact Mary Humphrey, Arizona Cancer Center, Univ. of Arizona College of Medicine, Tucson, AZ 85724, phone 602/626-2276, fax 602/626-2284.

**Third International Conference on the Interaction of Radiation Therapy and Systemic Therapy**--March 9-12, Asilomar Conference Center, Monterey, CA. Contact Suzanne Bohn, American College of Radiology, 1101 Market St., 14th Floor, Philadelphia, PA 19107, phone 215/574-3181.

**International Conference of Chronopharmacology & Chronotherapeutics**--March 12-15, Nice, France. Contact Dr. Alain Reinberg, Fondation A. de Rothschild, 29, rue Manin, 75940 Paris, Cedex 19 France, fax no. 1-4803-6590.

**Biology of Sarcomas**--March 11-16, Lake Tahoe, CA. Granlibakken Resort. Contact UCLA Symposia, 2032 Armacost Ave., Los Angeles, CA 90025.

**American College of Radiology 24th National Conference on Breast Cancer**--March 15-18, New Orleans, LA. Contact Educational Services, 1891 Preston White Dr., Reston, VA 22091, phone 703/648-8964.

**Fifth International Conference on Monoclonal Antibody Conjugates for Cancer**--March 15-17, San Diego, CA. Sheraton Harbor Island East Hotel. Contact Cass Jones, Professional Conference Management, 7916 Convoy Court, San Diego, CA 92111, phone 619/565-9921.

**Head and Neck Cancer Rehabilitation**--March 15-18, Dearborn, MI. Ritz Carlton Hotel. Contact Wayne State Univ. School of Medicine, Dept. of Otolaryngology, 4201 St. Antoine, 5E-UHC, Detroit, MI 48201, phone 313/577-0804.

**Community Cancer Care**--March 15, 22 and 29, Coraopolis, PA. Robert Morris College Moon Township Campus. Contact Denise Brooks, 412/624-7899.

**Symposium on Recent Advances in Cancer Therapy**--March 16-17, Denver, CO. Univ. of Colorado Cancer Center. Contact Cancer Education Office, phone 303/270-3005.

**Seventh Carolina Conference on Gene Transfer & Expression**--March 17-20, Wrightsville Beach, NC. Shell Island Resort. Contact Jo Ann McPherson, Univ. of North Carolina (Chapel Hill), Campus Box 7100, 101 MBBRL, Chapel Hill, NC 27599, phone 919/962-8920.

**International Society of Gynecological Endocrinology**--March 18-23, Jerusalem, Israel. Contact KENES LTD, PO Box 90006, Tel Aviv 61500, Israel.

**BACR 31st Annual Meeting & Assoc. of Cancer Physicians 5th Annual Meeting**--March 19-22, Brighton, UK. Contact B. Cavilla, Institute of Biology, 20 Queensberry Place, London SW7 2DZ, UK

**Div. of Cancer Biology & Diagnosis Board of Scientific Counselors**--March 19, NIH Bldg 31 Rm 9. Open 9:30 a.m.

**American Society of Preventive Oncology**--March 19-21, Bethesda, MD. Hyatt Regency-Bethesda. Contact Dr. Richard Love, ASPO, 1300 Univ. Ave.-7C, Madison, WI 53706, phone 608/263-6919.

**Health Effects of Omega-3 Polyunsaturated Fatty Acids in Seafoods**--March 20-23, Washington. Omni Shoreham Hotel. Contact Dr. Roy Martin, National Fisheries Institute, 2000 M St. NW Suite 580, Washington, D.C. 20036, phone 202/296-5172.

**Assoc. of Community Cancer Centers 16th Annual National Meeting**--March 21-24, Washington. Hyatt Washington on Capitol Hill. Contact ACCC, 11600 Nebel St. Suite 201, Rockville, MD 20852, phone 301/984-9496.

**ICN-UCI Symposium on Molecular Aspects of Development**--March 22-25, Dana Point, CA. Dana Point Resort Hotel. Contact

Nita Driscoll, ICN-UCI Symposium Office, Cancer Research Institute, Univ. of California, Irvine, CA 92727, phone 714/856-5886.

**Computerized Cytology & Histologic Laboratory**--March 24-27, Chicago. Contact International Academy of Cytology, 5841 Maryland Ave. HM 449, Chicago, IL 60615.

**International Symposium on Minimal Residual Disease in Acute Leukemia**--March 28-30, Rotterdam, Netherlands. Contact Congress Secretariat, Leukemia Symposium IMEDEX, Bruistensingel 144, 5232 AC's, Hertogenbosch, The Netherlands.

**Diagnosis and Treatment of Neoplastic Disorders: Medical, Surgical and Radiotherapeutic Aspects**--March 29-30, Johns Hopkins Medical Institutions, Baltimore, MD. Contact Office of Continuing Education, Turner Bldg, 720 Rutland Ave., Baltimore, MD 21205, phone 301/955-2959.

**Molecular Basis of Human Cancer**--March 29-30, Chapel Hill, NC. Contact Lineberger Cancer Research Center School of Medicine, Campus Box #7295, Univ. of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, phone 919/966-3036.

**American College of Surgeons Commission on Cancer: Cancer Management Course**--March 30-31, Washington Hospital Center, Washington. Contact Sharon Metzger, phone 202/877-6282.

#### FUTURE MEETINGS

**Entrepreneurship & Innovation for Physicians**--May 3-5, San Francisco, CA. Contact Center for Competition in Healthcare, Carol Bomar, phone 1-800-752-0926.

**Envisioning the Future: Oncology Social Work in the 1990s**--May 2-5, St. Petersburg Beach, FL. TradeWinds Hotel. Sponsored by National Assoc. of Oncology Social Workers. Contact Nancy Elkins, H. Lee Moffitt Cancer Center, PO Box 280179, Tampa, FL 33682, phone 813/972-8483.

**4th Drug Delivery Systems Symposium & 6th ISGIID Meeting**--June 20-23, Nice, France. Contact Secretariat Cardiostim 90, Departement de Stimulation Cardiaque, Centre Chirurgical Val D'Or, 16, rue Pasteur 92211 St. Cloud Cedex, France, phone (1)46.02.70.72.

**ASCO Fall Education Conference**--Oct 27-28, Anaheim, CA. Hilton Hotel. Contact American Society of Clinical Oncology, 435 N. Michigan Ave. Suite 1717, Chicago, IL 60611, phone 312/644-0828.

**International Assoc. for Breast Cancer Research Biennial Meeting**--May 27-29, 1991, Saint-Vincent, Italy. Contact Secretariat of the Meeting, Centro Congressi Grand Hotel Billia, 11027 Saint-Vincent, Aosta Valley, Italy, phone 0166/2011, fax 0166/201449.

## RFPs Available

Requests for proposals described here pertain to contracts planned for award by the National Cancer Institute unless otherwise noted. NCI listings will show the phone number of the Contracting Officer or Contract Specialist who will respond to questions. Address requests for NCI RFPs, citing the RFP number, to the individual named, the Executive Plaza South room number shown, National Cancer Institute, Bethesda MD 20892. Proposals may be hand delivered to the Executive Plaza South Building, 6130 Executive Blvd., Rockville MD. RFP announcements from other agencies will include the complete mailing address at the end of each.

### RFP NCI-CP-05635-13

Title: Record linkage studies utilizing resources in population based tumor registries (master agreements)

Deadline: Approximately March 23

This is the annual solicitation notice for 1990, issued by NCI, which is seeking qualified firms with population based cancer registries in the United States and other countries to collaborate in the conduct of record linkage and subsequent analytical studies.

The master agreement currently consists of 21 master agreement holders, under a four year master agreement which expires on March 14, 1992.

Offerors should have cancer incidence data for all patients diagnosed within a defined geographic locale during the last decade, 1978-1987. The offerors must have experience in the collection of cancer data from a variety of medical sources and multiple institutions. Offerors must have experience in obtaining information on vital status of cancer patients years after initial diagnosis. Offerors must have the legal authority to collect medical data within the given geographic area or else be able to demonstrate the willingness of all medical facilities within that area (including hospitals, clinics, private pathology laboratories, private radiotherapy facilities and nursing homes with diagnostic services) to participate in data collection and patient follow up activities.

Offerors must have the ability to obtain access to existing population based registries of exposed groups of individuals in the geographic areas covered by the cancer registry. Offerors must be willing to conduct collaborative research studies and analyses with the Epidemiology and Biostatistics Program and must be willing to permit the pooling of data with other cancer registries for combined analyses.

Master agreements will be awarded to all offerors whose technical proposal is considered acceptable. The initial master agreement award is nonmonetary, and is exclusively for the purpose of establishing a pool of contractors who are qualified to perform services for epidemiologic studies of cancer utilizing the resources of populations based cancer registries. Each master agreement holder will be eligible to compete for awards of master agreement orders to carry out specific record linkage and subsequent analytic studies. Master agreement holders receiving a master agreement order award will be selected from among those with a master agreement who choose to compete for the MAO/RFP, based on technical merit and budgetary considerations for the specific tasks involved.

Contracting Officer: Sharon Miller

RCB Executive Plaza South Rm 620  
301/496-8611

### RFP NCI-CM-07326-14

Title: Preparation of bulk chemicals and drugs for phase 2 and 3 clinical trials

Deadline: Approximately March 23

The Pharmaceutical Resources Branch in the Developmental Therapeutics Program of NCI's Div. of Cancer Treatment anticipates awarding two to three cost reimbursement incrementally funded contracts for a period of five years beginning on or about March 31, 1991, to provide and operate a materials preparation laboratory for the development of existing or new processes, procedures and techniques for the preparation of compounds, and the synthesis of varying amounts of materials, not readily available from other sources in the quantity or quality needed by NCI for the preparation of anticancer drugs for phase 2 and 3 clinical trials.

The successful offeror shall provide an operating large scale facility with at least one small (20-50 gallons) and one large (100 gallons or larger) glass lined reactor, and the necessary supporting equipment and facilities.

Quantities of drugs requested will usually range from 50 grams to multikilograms. Process development for scale up and access to pilot plant equipment is essential. Specific assignment of the materials for preparation will be made by NCI and may include synthesis of all types of chemicals and drugs. Quality specifications will be determined by the PRB, NCI. All materials

must be evaluated by the synthesis laboratory for identity and purity before being submitted to NCI.

The contractor's principal investigator should be trained in organic or medicinal chemistry, preferably at the Ph.D. level and have extensive experience in chemical synthesis and synthetic process development.

At the time of submission of best and final offers, the offeror must be registered with the FDA as a manufacturer of bulk drugs, and will have submitted a facilities Drug Master File to the FDA. Facilities shall meet FDA standards in accordance with the Current Good Manufacturing Practices, as well as be in compliance with applicable EPA and OSHA requirements and those of similar state and local agencies.

Two related RFPs are currently available. This RFP is a non restricted procurement, while RFP No. NCI-CM-07342-14, "Preparation of Bulk Chemicals and Drugs for Phase 2 and 3 Clinical Trials by Small Business" is a 100 percent small business set aside.

Contract Specialist: Mollie Shea

RCB Executive Plaza South Rm 603  
301/496-8620

#### RFP NCI-CM-07342-14

Title: Preparation of bulk chemicals and drugs for phase 2 and 3 clinical trials by small business

Deadline: Approximately March 23

The Pharmaceutical Resources Branch, Developmental Therapeutics Program of NCI's Div. of Cancer Treatment anticipates awarding two to three cost reimbursement incrementally funded contracts for a period of five years beginning on or about March 31, 1991, to provide and operate a materials preparation laboratory for the development of existing or new processes, procedures and techniques for the preparation of compounds, and the synthesis of varying amounts of materials, not readily available from other sources in the quantity or quality needed by NCI for the preparation of anticancer drugs for phase 2 and 3 clinical trials.

(See previous RFP for offeror requirements.)

This procurement is a total small business set aside. The Standard Industrial Classification number is 2854. Two related RFPs are currently available (see previous RFP). Offerors who qualify as a small business are encouraged to submit proposals under both RFPs; however, not more than one award of the available two to three awards (under both RFPs) will be made to any single offering organization.

Contract Specialist: Mollie Shea

RCB Executive Plaza South Rm 603  
301/496-8620

#### RFP NCI-CM-07328-28

Title: Synthesis of compounds for preclinical toxicology and phase 1 clinical studies

Deadline: Approximately March 23

The Pharmaceutical Resources Branch of the Developmental Therapeutics Program of NCI is seeking services in the area of synthesis of a variety of medicinal compounds which have been identified by the DTP for development, preclinical toxicology and phase 1 clinical trials.

One cost reimbursement contract is expected to be awarded to a contractor with the capability to provide and operate a materials preparation laboratory for (a) the development of existing or new processes, procedures and techniques for the preparation of compounds, and (b) the synthesis of varying amounts of materials, not readily available from other sources in the quantity and/or quality needed, as selected by NCI.

The successful offeror shall provide an operating large scale

facility with one small (20-50 gallons) and one large (100 gallons or larger) glass lined reactor and the necessary supporting equipment and facilities.

Quantities of drug requested will usually range from a few grams to multikilograms. Specific assignment of the materials for preparation will be made by NCI and may include a wide variety of medicinal compounds. Quality specifications will be determined by the Pharmaceutical Resources Branch. All materials must be assayed for identity and purity before being submitted to NCI.

The principal investigator should be trained in organic or medicinal chemistry, preferably at the Ph.D. level from an accredited school and have extensive experience in chemical synthesis and synthetic process development. The PI and all key personnel should be assigned to the project a minimum of 50 percent of the time. However, it is preferable that some key personnel be assigned to the project 100 percent of their time.

As a minimum requirement, the offeror must be registered with the FDA as a manufacturer of bulk drugs and shall have submitted a facilities Drug Master File to FDA at the time of the best and final offer. Facilities shall meet FDA standard in accordance with the Current Good Manufacturing Practices. Facilities shall also conform to applicable EPA and OSHA standards and those of comparable state and local agencies.

This is a recompetition of a contract currently held by Aldrich Chemical Co. Inc. NCI expects to award one cost reimbursement contract for a period of five years beginning on or about March 31, 1991.

Two related RFPs are currently available. This one is an open competition. RFP no. NCI-CM-07343-28, which follows, is a 100 percent small business set aside. Offerors who qualify as a small business are encouraged to submit proposals under both RFPs; however, only one award will be made to any single offering organization under this RFP NCI-CM-07328-28.

Contract Specialist: Carolyn Barker

RCB Executive Plaza South Rm 603  
301/496-8620

#### RFP NCI-CM-07343-28

Title: Synthesis of compounds for preclinical toxicology and phase 1 clinical studies for small business

Deadline: Approximately March 23

The Pharmaceutical Resources Branch of the Developmental Therapeutics Program of NCI is seeking services in the area of synthesis of a variety of medicinal compounds which have been identified by the DTP for development, preclinical toxicology and phase 1 clinical trials.

(See previous RFP for offeror requirements.)

As a minimum requirement, the offeror must be registered with the FDA as a manufacturer of bulk drugs and shall have submitted a facilities Drug Master File to FDA at the time of the best and final offer. Facilities shall meet FDA standard in accordance with the Current Good Manufacturing Practices. Facilities shall also conform to applicable EPA and OSHA standards and those of comparable state and local agencies.

This is a recompetition of a contract held by Starks Associates Inc. NCI expects to award one cost reimbursement contract for a period of five years beginning on or about March 31, 1991.

Two RFPs are currently available. This procurement is a total small business set aside. The Standard Industrial Classification number is 2854. The previous RFP is an open competition.

Offerors who qualify as a small business are encouraged to submit proposals under both RFPs; however, only one award will be made to any single offering organization.

Contract Specialist: Carolyn Barker

RCB Executive Plaza South Rm 603  
301/496-8620